CYP4A29 Activators
CYP4A29, a cytochrome P450 enzyme, exhibits predicted 16-hydroxypalmitate dehydrogenase and monooxygenase activities, playing a crucial role in fatty acid metabolic processes and icosanoid biosynthetic pathways. The predicted locations in the apical plasma membrane, cytoplasm, and extracellular space highlight the diverse cellular compartments where CYP4A29 may function. Its involvement in kidney development and implications in hypertension underline its importance in physiological and pathological contexts. Activation of CYP4A29 involves a repertoire of chemicals that directly or indirectly modulate its enzymatic activities. Wy-14643 and GW7647 directly activate CYP4A29 through peroxisome proliferator-activated receptor alpha (PPARα) activation, inducing increased transcription and elevated enzyme levels. Leukotriene B4 (LTB4) and 20-Hydroxyeicosatetraenoic Acid (20-HETE) directly stimulate CYP4A29 as substrates, promoting enzymatic activity in the icosanoid biosynthetic process. Fenofibrate, through PPARα activation, and 16-Hydroxypalmitate, as a substrate, further contribute to the direct activation of CYP4A29.
Indirect activators include Tazarotene, which modulates retinoic acid receptor (RAR) signaling, and epoxide hydrolase inhibitors, preventing the degradation of epoxyeicosatrienoic acids (EETs). Acetaminophen induces cytochrome P450 enzymes, indirectly activating CYP4A29 and enhancing fatty acid metabolism. Thiazolidinediones (TZDs) activate CYP4A29 through peroxisome proliferator-activated receptor gamma (PPARγ) modulation. Prostaglandin E2 (PGE2) directly stimulates CYP4A29 as a substrate, contributing to the autoregulatory loop in the metabolism of fatty acids. Understanding the specific pathways and molecules influencing CYP4A29 activation is vital for unraveling its role in fatty acid metabolism and icosanoid biosynthesis. The identified chemicals provide valuable insights into the diverse mechanisms underlying the regulation of CYP4A29, paving the way for further research into its functional significance in kidney development and its implications in hypertension.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $136.00 | 7 | |
Directly activates CYP4A29 through peroxisome proliferator-activated receptor alpha (PPARα) activation. Wy-14643 binding to PPARα induces its translocation into the nucleus, leading to increased transcription of CYP4A29. This results in elevated enzyme levels and enhanced 16-hydroxypalmitate dehydrogenase and monooxygenase activities. | ||||||
GW 7647 | 265129-71-3 | sc-203068A sc-203068 sc-203068B sc-203068C | 1 mg 5 mg 10 mg 25 mg | $49.00 $170.00 $267.00 $661.00 | 6 | |
Direct activator of CYP4A29 by binding to peroxisome proliferator-activated receptor alpha (PPARα). GW7647-activated PPARα translocates into the nucleus, leading to increased transcription of CYP4A29. This results in elevated enzyme levels and enhanced 16-hydroxypalmitate dehydrogenase and monooxygenase activities. | ||||||
Clofibrate | 637-07-0 | sc-200721 | 1 g | $33.00 | ||
Activates CYP4A29 by binding to peroxisome proliferator-activated receptor alpha (PPARα). Clofibrate-activated PPARα translocates into the nucleus, leading to increased transcription of CYP4A29. This results in elevated enzyme levels and enhanced 16-hydroxypalmitate dehydrogenase and monooxygenase activities. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Activates CYP4A29 through peroxisome proliferator-activated receptor alpha (PPARα) activation. Fenofibrate binding to PPARα induces its translocation into the nucleus, leading to increased transcription of CYP4A29. This results in elevated enzyme levels and enhanced 16-hydroxypalmitate dehydrogenase and monooxygenase activities. | ||||||
Tazarotene | 118292-40-3 | sc-220193 | 10 mg | $103.00 | ||
Acts as an indirect activator of CYP4A29 by modulating retinoic acid receptor (RAR) signaling. Tazarotene binds to RAR, promoting its interaction with retinoid X receptor (RXR). This heterodimer then binds to retinoic acid response elements in the CYP4A29 promoter, upregulating gene expression and subsequently increasing enzyme activity. | ||||||
Acetaminophen | 103-90-2 | sc-203425 sc-203425A sc-203425B | 25 g 100 g 500 g | $41.00 $61.00 $194.00 | 11 | |
Indirectly activates CYP4A29 by inducing cytochrome P450 enzymes. Acetaminophen metabolism generates reactive intermediates that stimulate various P450 enzymes, including CYP4A29. This indirect activation enhances the icosanoid biosynthetic process and monooxygenase activity, contributing to increased fatty acid metabolism. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Directly stimulates CYP4A29 by acting as a substrate. PGE2 is metabolized by CYP4A29 in the icosanoid biosynthetic process, and its binding to the enzyme's active site promotes enzymatic activity. This substrate-specific interaction serves as an autoregulatory mechanism, directly activating CYP4A29 in the metabolism of fatty acids. | ||||||